← Back to the boardHill
FDA is taking public comment through November 18, 2026 on its post-workshop strategy document covering BsUFA III future needs for interchangeable biosimilar development.
Why it’s here: This FDA docket on BsUFA III future needs for biosimilar interchangeable products is a federal regulatory comment period in the biotechnology policy area, though the item is a bare notice with little substance.
Item
11:59 PMAgencyFDAFDA is taking public comment through November 18, 2026 on its post-workshop strategy document covering BsUFA III future needs for interchangeable biosimilar development.Comment deadlineBiotechDetails
About
- Food and Drug Administration